BACKGROUND: Breast cancer is one of the leading cancers among females of Brunei Darussalam. There are four subtypes of breast cancer, including human epidermal growth factor receptor 2 (HER-2) positive breast cancer, which is known to be more aggressive and have a poor prognosis. AIM: This study aims to assess the proportion of HER-2 positive cases and the association of HER-2 positivity with patients' epidemiological and clinicopathological factors in Brunei Darussalam. METHODS AND RESULTS: A total of 146 breast cancer cases that were sent for fluorescence in situ hybridisation (FISH) analysis from 1 January 2012 to 31 December 2016 were obtained from The Brunei Cancer Centre, Brunei Darussalam. Data analysis was done with regards to age at diagnosis, ethnicity, stage at diagnosis and HER-2 results by immunohistochemistry (IHC) and FISH. Majority of the study population were diagnosed before the age of 50 years and the median age was 52.0 years. 58.2% (n = 85) cases were reported as IHC 3+, followed by 23.3% (n = 34) IHC 2+ cases and 18.5% (n = 27) negative cases. The proportion of true HER-2 positive cases in total by FISH analysis was 34.9% (n = 51). Majority of Stage IV HER-2 positive cases had metastases to the liver or bones. CONCLUSIONS: Age at diagnosis is significant in determining HER-2 status of tumours by FISH (P = .045). Tumour size (P < .001) and lymph node (P = .006) are significant in metastases of tumours. The proportion of HER-2 positive cases is consistent with findings from the Asian region but higher than that of Western countries. Determining false-positive and false-negative results by IHC test is important to ensure adequate treatment for patients with breast cancer.
BACKGROUND:Breast cancer is one of the leading cancers among females of Brunei Darussalam. There are four subtypes of breast cancer, including humanepidermal growth factor receptor 2 (HER-2) positive breast cancer, which is known to be more aggressive and have a poor prognosis. AIM: This study aims to assess the proportion of HER-2 positive cases and the association of HER-2 positivity with patients' epidemiological and clinicopathological factors in Brunei Darussalam. METHODS AND RESULTS: A total of 146 breast cancer cases that were sent for fluorescence in situ hybridisation (FISH) analysis from 1 January 2012 to 31 December 2016 were obtained from The Brunei Cancer Centre, Brunei Darussalam. Data analysis was done with regards to age at diagnosis, ethnicity, stage at diagnosis and HER-2 results by immunohistochemistry (IHC) and FISH. Majority of the study population were diagnosed before the age of 50 years and the median age was 52.0 years. 58.2% (n = 85) cases were reported as IHC 3+, followed by 23.3% (n = 34) IHC 2+ cases and 18.5% (n = 27) negative cases. The proportion of true HER-2 positive cases in total by FISH analysis was 34.9% (n = 51). Majority of Stage IV HER-2 positive cases had metastases to the liver or bones. CONCLUSIONS: Age at diagnosis is significant in determining HER-2 status of tumours by FISH (P = .045). Tumour size (P < .001) and lymph node (P = .006) are significant in metastases of tumours. The proportion of HER-2 positive cases is consistent with findings from the Asian region but higher than that of Western countries. Determining false-positive and false-negative results by IHC test is important to ensure adequate treatment for patients with breast cancer.
Authors: Raymond Jih Yeong Chong; Mohd Syafiq Abdullah; Mohammad Moshaddeque Hossain; Pemasari Upali Telisinghe; Vui Heng Chong Journal: Asian Pac J Cancer Prev Date: 2013
Authors: Aleodor A Andea; Tracie Wallis; Lisa A Newman; David Bouwman; Jyotirmoy Dey; Daniel W Visscher Journal: Cancer Date: 2002-03-01 Impact factor: 6.860
Authors: Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544